Replies to post #2217 on Biotech Values

[mskatiescarletohara]

Bravo Dew on your excellent hypothesis regarding OXGN's trial, it appears your take is now reality.

I am wondering how Dai Chaplin can state OXGN is awaiting more significant data from this study. I'm also confused by the statement regarding one patient. See below.

The area of choroidal neovasculariztion (CNV) in the patient's study eye decreased by approximately 100 microns, a reduction that Dr. Campochiaro said was "not within the realm of spontaneous changes." CNV occurs when abnormal blood vessels sprout behind the retina, leaking blood and other fluid into the retina and triggering the sudden and severe central vision loss known as wet AMD

Was it therapeutically favorable for this patient to not experience spontaneous changes. My first impression was CA4P did not cause any spontaneous changes due to the dosage.

Please clarify.

katie...

[isolution]

OXGN interim results


While instances of hypertension were noted in the Phase I/II study by Dr. Campochiaro, he indicated that a local method of delivery could substantially reduce systemic exposure to CA4P and further improve its safety profile in this clinical setting. [Translation: CA4P is probably too toxic for *systemic* treatment in AMD]

I agree dew and it also makes a rationale with their choice of conducting a clinical trial on patients having myopic macular degeneration [Translation: young population of patients - about 40 years old - less prone to have cardiac problems]

Regards